State of the Art of Antiemetic Therapy
Authors:
- 28 June 2018
- book chapter
- Published by Springer Nature
- p. 461-480
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III studySupportive Care in Cancer, 2010
- Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapySupportive Care in Cancer, 2010
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupportive Care in Cancer, 2010
- Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statementSupportive Care in Cancer, 2010
- Aprepitant: drug–drug interactions in perspectiveAnnals of Oncology, 2010
- Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapyAnnals of Oncology, 2010
- Anti‐Emetic Therapy in Cancer Chemotherapy: Current StatusBasic & Clinical Pharmacology & Toxicology, 2007
- Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatmentAnnals of Oncology, 2006
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonistCancer, 2003